About Us

AAX Biotech AB is a research-driven biotech company with proprietary technologies that solve unmet needs in the development of next-generation antibody therapeutics.

We offer a unique solution to a recognized problem in a rapidly growing market. AAX's two unique and patentable technologies improve the performance and developability of antibody-based therapeutics.

With the Seqitope™ technology, drug developers can accelerate drug development by resolving in detail epitope-binding properties at an early stage. Our second technology – Opti-mAb™ – is a molecular stabilization strategy for scFv antibodies, providing significantly more stable, non-aggregating and therefore cost-effective drug development and improved pharmacological properties.

Our History

AAX Biotech was spun out from Karolinska Institutet by co-founders and experts in the field Mats Persson and Daniel Johansson, who developed new innovative solutions out of a need to significantly improve therapeutics used to enhance patients’ lives.

While the name AAX Biotech reveals that we are “Advanced Antibody Explorers”, it also builds on the founders’ scientific aliases, Mats AA Persson and Daniel X Johansson.

The Team

  • Maria Lisa Knudsen

    CEO

  • Daniel X Johansson

    CSO & Co-Founder

  • Juan Astorga Wells

    Sr. Manager of Science & Development

  • Mats AA Persson

    Advisor & Co-Founder

  • Anders Andersson

    Consultant

  • Kristina Magnusson Borg

    Business Coach

Board of Directors

  • Svante Almkvist

    Chair

  • Emmelie Persson

    Board Member

  • Mats AA Persson

    Board Member

  • Daniel X Johansson

    Board Member

  • Maria Lisa Knudsen

    Adjunct Board Member

Mission and Vision

We aim to contribute to the development of next-generation therapies against all diseases, including cancer, autoimmune diseases, and neurological diseases. Our goal is to be a leading player in the antibody field and an obvious partner for pharma companies.

Our mission is to leverage science and innovation to solve unmet needs in developing next-generation therapeutics. Our technologies aim to produce better and more effective antibody-based medicines, and to enable other antibody developing companies excel in solving their technical difficulties.

Our vision is to improve patient lives by establishing AAX as a leading, highly competitive partner serving the bio-pharma industry worldwide and being the superior choice for antibody development.